CA2483857A1 - Use of dimesna for mitigating taxane induced neurotoxicity - Google Patents

Use of dimesna for mitigating taxane induced neurotoxicity Download PDF

Info

Publication number
CA2483857A1
CA2483857A1 CA002483857A CA2483857A CA2483857A1 CA 2483857 A1 CA2483857 A1 CA 2483857A1 CA 002483857 A CA002483857 A CA 002483857A CA 2483857 A CA2483857 A CA 2483857A CA 2483857 A1 CA2483857 A1 CA 2483857A1
Authority
CA
Canada
Prior art keywords
taxane
antineoplastic agent
drug
taxane antineoplastic
ethane sulfonate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002483857A
Other languages
English (en)
French (fr)
Inventor
Frederick H. Hausheer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BioNumerik Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2483857A1 publication Critical patent/CA2483857A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002483857A 2002-04-30 2003-04-29 Use of dimesna for mitigating taxane induced neurotoxicity Abandoned CA2483857A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/135,975 US8710095B2 (en) 2002-04-30 2002-04-30 Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity
US10/135,975 2002-04-30
PCT/US2003/013518 WO2003092675A1 (en) 2002-04-30 2003-04-29 Drugs for mitigating taxane-induced neurotoxicity

Publications (1)

Publication Number Publication Date
CA2483857A1 true CA2483857A1 (en) 2003-11-13

Family

ID=29249584

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002483857A Abandoned CA2483857A1 (en) 2002-04-30 2003-04-29 Use of dimesna for mitigating taxane induced neurotoxicity

Country Status (8)

Country Link
US (1) US8710095B2 (enExample)
EP (1) EP1503748B1 (enExample)
JP (2) JP5416327B2 (enExample)
AT (1) ATE554753T1 (enExample)
AU (1) AU2003225253B2 (enExample)
CA (1) CA2483857A1 (enExample)
ES (1) ES2381968T3 (enExample)
WO (1) WO2003092675A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8710095B2 (en) * 2002-04-30 2014-04-29 Bionumerik Pharmaceuticals, Inc. Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity
US20090111735A1 (en) * 2004-05-12 2009-04-30 Bionumerik Pharmaceuticals, Inc. Compounds and methods for reducing undesired toxicity of chemotherapeutic agents
WO2007070599A2 (en) * 2005-12-13 2007-06-21 Bionumerik Pharmaceuticals, Inc. Chemoprotective methods and compositions
WO2007109184A2 (en) * 2006-03-16 2007-09-27 Bionumerik Pharmaceuticals, Inc. Anti-cancer activity augmentation compounds and formulations and methods of use thereof
EP2191836B1 (en) * 2007-08-31 2012-05-23 Kyushu University, National University Corporation Prophylactic or alleviating agent for peripheral nerve disorder induced by anti-cancer agent
JP5696266B2 (ja) 2007-11-20 2015-04-08 ランケナー インスティテュート フォー メディカル リサーチ ジスルフィド化学療法剤およびその使用方法
WO2009113984A1 (en) * 2008-03-14 2009-09-17 Bionumerik Pharmaceuticals, Inc. Chemoprotective methods and compositions
US9320760B2 (en) * 2008-03-14 2016-04-26 Bionumerik Pharmaceuticals, Inc. Compositions and methods of use of compounds to increase cancer patient survival time
EP2249826B1 (en) * 2008-03-14 2016-09-07 Bionumerik Pharmaceuticals, Inc. Compositions and methods of use of compounds to increase cancer patient survival time
EP2249825B1 (en) * 2008-03-14 2015-10-07 Bionumerik Pharmaceuticals, Inc. Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions
US20090232906A1 (en) * 2008-03-14 2009-09-17 Bionumerik Pharmaceuticals, Inc. Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions
NZ601635A (en) 2010-01-27 2013-06-28 Takeda Pharmaceutical Compounds for suppressing a peripheral nerve disorder induced by an anti-cancer agent
US11471431B2 (en) * 2010-09-16 2022-10-18 Lantern Pharma Inc. Increasing cancer patient survival time by administration of dithio-containing compounds
EP3068411B1 (en) * 2013-11-15 2020-03-18 Oncolytics Biotech Inc. Oncolytic viruses and increased cancer treatment regimens
AU2017384134B2 (en) * 2016-12-19 2022-03-24 Merck Patent Gmbh Combination of a protein kinase inhibitor and an additional chemotherapeutic agent
WO2018194976A1 (en) * 2017-04-17 2018-10-25 Indiana University Research And Technology Corporation Prevention and reversal of inflammation induced dna damage

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3140093A (en) * 1991-11-22 1993-06-15 University Of Mississippi, The Synthesis and optical resolution of the taxol side chain and related compounds
FR2722987B1 (fr) * 1994-07-29 1997-05-16 Synthelabo Utilisation de l'eliprodil et de ses enantiomeres pour la preparation de medicaments utiles dans la prevention des neuropathiesinduites par des agentsanticancereux
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US6025488A (en) * 1994-11-14 2000-02-15 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US5789000A (en) * 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
DE19617802A1 (de) * 1996-05-03 1997-11-06 Basf Ag Verfahren zur heterogen katalysierten Herstellung von Hydroxyalkyl-substituierten Aminoalkinen
US6037336A (en) * 1996-09-23 2000-03-14 Bionumerik Pharmaceuticals, Inc. Reducing toxic effects of carboplatin using dithioethers
CA2263166C (en) 1996-09-23 2006-12-12 Bionumerik Pharmaceuticals, Inc. Reducing toxic effects of carboplatin using dithioethers
ES2163197T3 (es) 1996-10-01 2002-01-16 Bionumerik Pharmaceuticals Inc Procedimiento para producir ditiobis-alcanosulfonatos y fosfonatos.
US6160167A (en) 1998-04-21 2000-12-12 Bionumerik Pharmaceuticals, Inc. Mercaptans and disulfides
US6177411B1 (en) 1999-02-09 2001-01-23 Bionumerik Pharmaceuticals, Inc. Method for treating heavy metal poisoning
US6172119B1 (en) 1999-02-09 2001-01-09 Bionumerik Pharmaceuticals, Inc. Method of treating acute renal failure
US6197831B1 (en) 1999-02-09 2001-03-06 Bionumerik Pharmaceuticals, Inc. Method of treating septic shock
US5998479A (en) 1999-02-09 1999-12-07 Bionumerik Pharmaceuticals, Inc. Method of treating adult respiratory syndrome
US6075053A (en) 1999-02-09 2000-06-13 Bionumerik Pharmaceuticals, Inc. Method of reducing or reversing neuropathy
US6034126A (en) 1999-05-24 2000-03-07 Bionumerik Pharmaceuticals, Inc. Method for treating glycol poisoning
US6077838A (en) 1999-06-08 2000-06-20 Bionumerik Pharmaceuticals, Inc. Method of treating hangover
US6143796A (en) 1999-09-02 2000-11-07 Bionumerik Pharmaceuticals, Inc. Method for reducing development of free radical induced malignancies
US6468993B1 (en) 1999-10-04 2002-10-22 Bionumerik Pharmaceuticals, Inc. Method for reducing development of osteoporosis
US6031006A (en) 1999-10-21 2000-02-29 Bionumerik Pharmaceuticals, Inc. Method of treating diabetic nephropathy
US6251881B1 (en) 1999-10-21 2001-06-26 Frederick H. Hausheer Method of treating diabetic angiopathy
US6043274A (en) 1999-10-21 2000-03-28 Bionumerik Pharmaceuticals, Inc. Method of treating diabetic cardiomyopathy
US6100247A (en) 1999-10-21 2000-08-08 Bionumerik Pharmaceuticals, Inc. Method of treating diabetic neuropathy
US6274622B1 (en) 1999-10-27 2001-08-14 Frederick H. Hausheer Method of treating diabetic ophthalmopathy
US6525037B1 (en) 2000-02-25 2003-02-25 Bionumerik Pharmaceuticals, Inc. Method of treating atherosclerosis and complications resulting therefrom
AU2000239101A1 (en) * 2000-03-22 2001-10-03 Neopharm, Inc. A method of administering liposomal encapsulated taxane
US6245815B1 (en) 2000-04-15 2001-06-12 Bionumerik Pharmaceuticals, Inc. Method of treating alcoholism and complications resulting therefrom
US6468963B1 (en) 2000-05-01 2002-10-22 Bionumerik Pharmaceuticals, Inc. Methods and formulations for reducing toxicity associated with diabetes treatments
FR2811987A1 (fr) 2000-07-18 2002-01-25 Expansia Sa Procede de preparation du 2,2'-dithiobis(ethanesulfonate) de disodium
US6225295B1 (en) 2000-09-27 2001-05-01 Frederick H. Hausheer Method of treating acetaminophen overdose
US6291441B1 (en) 2000-09-27 2001-09-18 Frederick H. Hausheer Method of treating inflammatory bowel disorders
US6255355B1 (en) 2001-01-06 2001-07-03 Seetharamulu Peddaiahgari Method of inhibiting angiogenesis
JP2004523518A (ja) 2001-01-19 2004-08-05 バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド より効能が大きく副作用の少ない癌治療方法
US6352979B1 (en) 2001-08-20 2002-03-05 Lucinda Lizcano Method of treating snakebite and complications resulting therefrom
US7176192B2 (en) 2001-10-26 2007-02-13 Bionumerik Pharmaceuticals, Inc. Method for treating patients for radiation exposure
US6596320B1 (en) * 2002-01-11 2003-07-22 Bionumerik Pharmaceuticals, Inc. Method for treating cancer having greater efficacy and reduced adverse effects
US6504049B1 (en) 2002-04-30 2003-01-07 Bionumerik Pharmaceuticals, Inc. Process for synthesizing pharmaceutically active disulfide salts
US8710095B2 (en) * 2002-04-30 2014-04-29 Bionumerik Pharmaceuticals, Inc. Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity
US20040014730A1 (en) 2002-07-10 2004-01-22 Frederick Hausheer Formulations and methods of reducing toxicity of anti-infective agents
EP1583540A4 (en) 2002-12-21 2006-07-26 Bionumerik Pharmaceuticals Inc METHOD FOR THE TREATMENT OF TOXIC CHEMICALS EMITTED PATIENTS
US20040152774A1 (en) 2003-02-04 2004-08-05 Hausheer Frederick H. Method of protecing against tissue extra vasation injury
WO2005058005A2 (en) 2003-12-17 2005-06-30 Bionumerik Pharmaceuticals, Inc. Process for synthesizing disulfides

Also Published As

Publication number Publication date
EP1503748B1 (en) 2012-04-25
US8710095B2 (en) 2014-04-29
WO2003092675A1 (en) 2003-11-13
JP2011140521A (ja) 2011-07-21
EP1503748A1 (en) 2005-02-09
ATE554753T1 (de) 2012-05-15
AU2003225253A1 (en) 2003-11-17
JP5416327B2 (ja) 2014-02-12
US20030203960A1 (en) 2003-10-30
JP2005525409A (ja) 2005-08-25
AU2003225253B2 (en) 2008-09-04
EP1503748A4 (en) 2009-10-21
ES2381968T3 (es) 2012-06-04

Similar Documents

Publication Publication Date Title
AU2003225253B2 (en) Drugs for mitigating taxane-induced neurotoxicity
Pasetto et al. Oxaliplatin-related neurotoxicity: how and why?
AU2014251087B2 (en) Formulations of oxabicycloheptanes and oxabicycloheptenes
CN100411628C (zh) 空间位阻的铂配位化合物与非铂抗癌剂的组合及其应用
NZ510504A (en) Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin
JP2005525409A5 (enExample)
US4609647A (en) Cytidyl diphosphocholine-drug composition and process
KR20020060226A (ko) 배합 화학요법
MXPA04006822A (es) Combinaciones que comprenden epotilonas y anti-metabolitos.
EP1273296B1 (en) Combination of acetyldinaline and docetaxel
US7998973B2 (en) Tivozanib and temsirolimus in combination
EP3127544B1 (en) Anti-tumor drug containing anti-tumor platinum complex, and anti-tumor effect enhancer
JP2004523518A (ja) より効能が大きく副作用の少ない癌治療方法
AU2002251763A1 (en) Method for treating cancer
CN119816307A (zh) 包含flt3抑制剂的癌症组合疗法
US20040086536A1 (en) Therapeutic agents and treatment kits for hypertrophic pyloric stenosis
US20030134893A1 (en) Combination chemotherapy
MX2011006253A (es) Combinacion antitumoral que asocia ave8062 y docetaxel.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20121001

FZDE Discontinued

Effective date: 20121001